Glyburide
- Generic Name
- Glyburide
- Brand Names
- Diabeta, Glucovance, Glynase, Amglidia
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28ClN3O5S
- CAS Number
- 10238-21-8
- Unique Ingredient Identifier
- SX6K58TVWC
- Background
Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II. It is typically given to patients who cannot be managed with the standard first line therapy, metformin. Glyburide stimulates insulin secretion through the closure of ATP-sensitive potassium channels on beta cells, raising intracellular potassium and calcium ...
- Indication
Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Gestational Diabetes Mellitus (GDM), Glycemic Control, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Cardioprotective Effects of GLP-1 and Their Mechanisms
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2016-04-11
- Lead Sponsor
- Papworth Hospital NHS Foundation Trust
- Target Recruit Count
- 32
- Registration Number
- NCT02128022
- Locations
- 🇬🇧
Papworth Hospital, Cambridge, Cambridgeshire, United Kingdom
Oral Antidiabetic Agents in Pregnancy
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 80
- Registration Number
- NCT02091336
- Locations
- 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
A Feasibility Study Looking at the Use of Glibenclamide and metfoRmin Versus stAndard Care in gEstational diabeteS
- Conditions
- Interventions
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- University of Edinburgh
- Target Recruit Count
- 23
- Registration Number
- NCT02080377
- Locations
- 🇬🇧
St Johns Hospital, Livingston, West Lothian, United Kingdom
🇬🇧Princess Royal Infirmary, Glasgow, Lanarkshire, United Kingdom
🇬🇧Western General Hospital, Edinburgh, Lothian, United Kingdom
Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide
- Conditions
- Interventions
- First Posted Date
- 2013-09-20
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- University of Pittsburgh
- Registration Number
- NCT01947699
- Locations
- 🇺🇸
Magee Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-04-02
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Azienda Ospedaliero-Universitaria di Parma
- Target Recruit Count
- 64
- Registration Number
- NCT01822548
- Locations
- 🇮🇹
Azienda Opedaliera-Universitaria, Parma, Italy
🇮🇹Azienda Ospedaliera-Universitaria, Parma, Italy
A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Glyburide in Healthy Volunteers
- First Posted Date
- 2012-11-26
- Last Posted Date
- 2012-12-12
- Target Recruit Count
- 29
- Registration Number
- NCT01733108
Multicenter Randomized Trial of Non-inferiority Between Glyburide and Insulin for the Treatment of Gestational Diabetes
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2017-12-08
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 914
- Registration Number
- NCT01731431
- Locations
- 🇫🇷
Marie-Victoire Senat, Paris, France
Glyburide Healthy Volunteer Study
- First Posted Date
- 2012-10-29
- Last Posted Date
- 2014-09-16
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 21
- Registration Number
- NCT01716338
- Locations
- 🇺🇸
Washington University in St. Louis Clinical Research Unit (CRU), St. Louis, Missouri, United States
Efficacy of Repaglinide in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 9
- Registration Number
- NCT01698931
- Locations
- 🇮🇹
Novo Nordisk Investigational Site, Padova, Italy
Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 51
- Registration Number
- NCT01605773
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.